GLP-1 vs GIP: Understanding the Difference

GLP-1 vs GIP- GLP-1 and GIP are two naturally occurring hormones that play key roles in regulating blood sugar, appetite, digestion, and energy metabolism. Both belong to a group of hormones called incretins, which the gut releases after eating.

Interest in GLP-1 and GIP has increased significantly because medicines that act on these hormone pathways are used to manage type 2 diabetes and, in some cases, obesity or chronic weight management. Some newer medicines target both pathways at the same time, creating an important distinction between GLP-1-only therapies and dual GLP-1/GIP therapies.

So, what exactly is the difference between GLP-1 and GIP? How do they work, and why are both important in modern metabolic medicine?

What Is GLP-1?

GLP-1, or glucagon-like peptide-1, is an incretin hormone produced mainly by specialised cells in the intestine after you eat.

One of its major functions is helping the body respond appropriately to rising blood glucose levels. GLP-1 can stimulate insulin secretion when glucose levels are elevated and can reduce glucagon secretion. Together, these effects can help lower blood glucose.

GLP-1 also affects the digestive system and brain. It can slow gastric emptying, meaning food may move more slowly from the stomach into the small intestine. This can contribute to greater feelings of fullness after eating.

GLP-1 receptors are found in several tissues, including the pancreas and areas of the brain involved in appetite regulation. Because of these effects, medications that activate GLP-1 receptors are often called GLP-1 receptor agonists.

Examples of medicines that act primarily through the GLP-1 pathway include semaglutide and liraglutide.

What Is GIP?

GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone. It is released mainly from cells in the upper part of the small intestine after food enters the digestive tract.

Like GLP-1, GIP can increase insulin secretion in response to elevated blood glucose. However, GIP has its own physiological effects and works through a different receptor.

GIP receptors are found in pancreatic cells and other tissues. Research has also investigated GIP’s role in fat metabolism, energy balance, and the central nervous system.

GIP’s effects are therefore not identical to those of GLP-1. The two hormones interact with different receptors and can influence metabolism through overlapping as well as distinct pathways.

GLP-1 vs GIP: Key Differences

Although GLP-1 and GIP are both incretin hormones, they are different hormones and do not have identical effects.

Feature	GLP-1	GIP
Full name	Glucagon-like peptide-1	Glucose-dependent insulinotropic polypeptide
Hormone type	Incretin	Incretin
Main source	Intestinal L cells	Intestinal K cells
Major role	Blood glucose regulation, appetite and gastric emptying	Insulin response and metabolic regulation
Main receptor	GLP-1 receptor	GIP receptor
Effect on insulin	Increases glucose-dependent insulin secretion	Increases glucose-dependent insulin secretion
Effect on glucagon	Can suppress glucagon when glucose is elevated	Effects vary with metabolic conditions
Gastric emptying	Can slow gastric emptying	Generally less prominent effect
Therapeutic research	Extensive clinical use	Increasingly important in combination therapies

These differences help explain why researchers have become interested in targeting both pathways simultaneously.

How Does GLP-1 Affect Blood Sugar?

After eating, increased blood glucose can trigger the release of GLP-1. GLP-1 then helps regulate glucose through several mechanisms.

First, it can increase insulin secretion from pancreatic beta cells when blood glucose is elevated. Insulin helps glucose move from the bloodstream into cells where it can be used or stored.

Second, GLP-1 can reduce glucagon secretion when glucose is elevated. Glucagon normally signals the liver to release glucose into the bloodstream.

Third, GLP-1 can slow gastric emptying. This may slow the rate at which nutrients enter the bloodstream following a meal.

Because GLP-1 activity is glucose-dependent, its insulin-related effects are generally more pronounced when blood glucose is elevated.

How Does GIP Affect Blood Sugar?

GIP also contributes to the body’s response to food. One of its best-established effects is stimulating insulin secretion in a glucose-dependent manner.

GIP can therefore help maintain appropriate blood glucose after meals.

GIP also has effects beyond the pancreas. Researchers have studied its potential role in adipose tissue, lipid metabolism, and the brain.

Importantly, GIP’s biological effects can depend on the metabolic environment. This complexity is one reason GIP has become an important research focus in diabetes and obesity medicine.

Why Are GLP-1 and GIP Being Studied Together?

One of the most important developments in incretin-based medicine is the development of treatments that activate both GLP-1 and GIP receptors.

The rationale is relatively straightforward: GLP-1 and GIP have overlapping effects, but they also influence different biological pathways.

A medicine that activates both receptors may therefore produce a broader metabolic response than activation of either pathway alone.

Tirzepatide is a well-known example of a medicine that acts on both the GIP and GLP-1 receptors. It is classified as a dual GIP/GLP-1 receptor agonist.

The development of dual incretin therapies has expanded research into how multiple hormonal pathways can be targeted simultaneously.

GLP-1 vs Dual GLP-1/GIP Medicines

It is useful to distinguish between a traditional GLP-1 receptor agonist and a dual GLP-1/GIP receptor agonist.

A GLP-1 receptor agonist primarily activates the GLP-1 receptor. Semaglutide and liraglutide are examples.

A dual GIP/GLP-1 receptor agonist activates both the GIP and GLP-1 receptors. Tirzepatide is an example.

This does not mean that one mechanism is automatically appropriate for everyone. Treatment selection depends on factors such as the individual’s medical condition, treatment goals, other medications, contraindications, and clinical history.

GLP-1, GIP and Appetite

Another reason these hormones have attracted attention is their relationship with appetite and food intake.

GLP-1 signaling can influence areas of the brain involved in appetite regulation. It can also delay gastric emptying, which may contribute to fullness.

GIP is also being studied for its effects on energy balance and the central nervous system. When GIP and GLP-1 pathways are activated together, researchers have investigated whether their combined effects can influence appetite and metabolic regulation.

However, appetite regulation is complex. It involves hormones, the nervous system, digestion, food environment, sleep, behaviour, and many other factors.

GLP-1 vs GIP for Weight Management

GLP-1-based medicines have become widely discussed for chronic weight management because they affect appetite, food intake, and metabolic regulation.

Research into GIP has expanded considerably, particularly because dual GIP/GLP-1 medicines have demonstrated substantial effects on body weight in clinical trials.

However, do not assume hormone names alone determine a medicine’s effectiveness. A medicine’s overall effects depend on its pharmacology, dosage, formulation, treatment duration, patient population, and clinical evidence.

For someone considering treatment for obesity or overweight, the appropriate approach should be discussed with a qualified healthcare professional rather than selected solely on the basis of whether a medicine targets GLP-1, GIP, or both.

What Are Common Side Effects of Incretin-Based Medicines?

Medicines that affect GLP-1 or GLP-1/GIP signalling can cause gastrointestinal side effects.

Commonly reported effects may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort
• Reduced appetite

These effects vary by individual and may change during treatment.

Some adverse effects can be more serious, so patients should follow the prescribing information and discuss concerning symptoms with their healthcare professional.

People should also avoid assuming that a medication is suitable simply because it belongs to a particular hormone class. Medical history and individual risk factors are important when evaluating treatment.

Are GLP-1 and GIP the Same Thing?

No. GLP-1 and GIP are separate hormones with different receptors and overlapping but distinct physiological effects.

Both are incretin hormones, and both can stimulate glucose-dependent insulin secretion. However, GLP-1 has more prominent effects on gastric emptying and appetite regulation, while GIP has additional effects that researchers are investigating in areas such as adipose tissue and energy metabolism.

Modern medicines can target one pathway or both pathways simultaneously.

GLP-1 vs GIP: Which Pathway Is Better?

There is no universal answer.

GLP-1 and GIP have different biological functions, and medicines targeting these pathways have different clinical profiles. Treatment decisions also depend on the specific medicine, not just the hormone it targets.

For example, comparing a GLP-1 receptor agonist with a dual GIP/GLP-1 receptor agonist involves looking at clinical trial evidence, approved indications, dosing, effectiveness, adverse effects, contraindications, and the patient’s individual circumstances.

Therefore, the most useful question is often not simply “GLP-1 vs GIP,” but which treatment has appropriate evidence and an acceptable risk-benefit profile for a particular patient and medical condition?

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone involved in blood glucose regulation, insulin secretion, gastric emptying, and appetite signalling.

What does GIP stand for?

GIP stands for glucose-dependent insulinotropic polypeptide. It is an incretin hormone that plays an important role in glucose-dependent insulin secretion and has other metabolic effects.

Is tirzepatide a GLP-1 medicine?

Tirzepatide activates both the GIP and GLP-1 receptors, so it is generally described as a dual GIP/GLP-1 receptor agonist rather than a GLP-1-only medicine.

Is semaglutide a GIP medicine?

Semaglutide is a GLP-1 receptor agonist. It does not directly activate the GIP receptor.

Why are GIP and GLP-1 being combined?

Researchers are studying combined GIP and GLP-1 receptor activation because the two pathways overlap but have distinct biological effects. Dual-pathway medicines are designed to activate both receptors.

Final Thoughts

GLP-1 and GIP are closely related because both are incretin hormones, but they are biologically distinct. GLP-1 plays an important role in glucose regulation, insulin secretion, gastric emptying, and appetite signalling. GIP also promotes glucose-dependent insulin secretion and has additional metabolic effects.

The development of medicines that target both pathways has made the GLP-1 vs GIP distinction increasingly important. Rather than viewing the hormones as competing alternatives, it is more accurate to understand them as separate components of the body’s complex metabolic system.

For patients, treatment decisions should be based on approved indications, clinical evidence, individual medical circumstances, and guidance from a qualified healthcare professional. Hormone-based medicines should not be started, stopped, or changed without appropriate medical advice.